文献速递血栓与止血

比较A型血友病患者与维生素K拮抗剂治疗患者的凝血酶生成

Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
PubMed 文献 · J Thromb Haemost · 2017-04-13

横断面研究以1pM组织因子启动凝血酶生成,比较133例重型(FVIII<1%,n=15)和非重型(FVIII 1-50%,n=118)A型血友病患者、97例INR≥1.5的VKA治疗患者及健康对照的内源性凝血酶潜能(ETP)。重型血友病患者ETP与治疗INR患者相当,非重型患者中约三分之一ETP高于治疗INR水平。

要点

  • 重型血友病患者ETP与治疗INR患者相当。
  • 非重型血友病患者中约三分之一ETP高于治疗INR水平。
  • 治疗INR患者ETP均<400,重型血友病93%低于此阈值。

核心结论

  • 重型血友病患者凝血酶生成与治疗INR患者相当,约三分之一非重型血友病患者凝血酶生成更高,作者认为相当比例非重型血友病患者应考虑抗凝治疗。

研究设计与样本

  • 横断面研究,纳入133例A型血友病患者(重型FVIII<1%者15例,非重型FVIII 1-50%者118例)、97例INR≥1.5的VKA治疗患者及健康对照,以1pM组织因子启动凝血酶生成,计算ETP中位数和四分位距(IQR)。

主要发现

  • 健康对照ETP中位数为898(IQR 803-1004),血友病患者为304(196-449),VKA治疗患者为176(100-250)。
  • 重型血友病患者ETP为185(116-307),治疗INR患者为156(90-225)。
  • FVIII 1-19%患者ETP为296(203-430),FVIII 20-50%患者为397(219-632),均高于治疗INR患者。
  • 所有治疗INR患者ETP<400;以400为阈值,重型血友病患者93%、FVIII 1-19%患者70%、FVIII 20-50%患者52%的ETP<400。

临床怎么用

  • 作者认为,相当比例的非重型血友病患者应考虑抗凝治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials It is unknown if hemophilia patients with atrial fibrillation need anticoagulation. Endogenous thrombin potentials (ETP) in hemophilia patients and patients on coumarins were compared. Severe hemophilia patients had comparable ETP to therapeutic international normalized ratio (INR). In non-severe hemophilia, 33% had higher ETP than therapeutic INR and may need anticoagulation. Click to hear Dr Negrier's perspective on global assays for assessing coagulation SUMMARY: Background It is unknown whether patients with hemophilia A with atrial fibrillation require treatment with vitamin K antagonists (VKAs) to the same extent as the normal population. Objective To compare hemostatic potential in hemophilia patients and patients on VKAs using thrombin generation (TG). Methods In this cross-sectional study, TG, initiated with 1pM tissue factor, was measured in 133 patients with severe (FVIII < 1%, n = 15) and non-severe (FVIII 1-50%, n = 118) hemophilia A, 97 patients on a VKA with an international normalized ratio (INR) ≥ 1.5 and healthy controls. Endogenous thrombin potential (ETP) (nm*min) was compared according to FVIII level (< 1%, 1-19% and 20-50%) with healthy controls and patients with sub-therapeutic INR (1.5-1.9) and therapeutic INR (≥ 2.0). Medians and interquartile ranges (IQRs) were calculated. Results Compared with healthy controls (898 [IQR 803-1004]), both hemophilia patients and patients on VKAs had lower median ETPs at 304 (196-449) and 176 (100-250), respectively. ETP was quite similar in severe hemophilia patients (185 [116-307]) and patients with a therapeutic INR (156 [90-225]). Compared with patients with therapeutic INR, ETP in patients with FVIII 1-19% and patients with FVIII 20-50% was higher at 296 (203-430) and 397 (219-632), respectively. All patients with therapeutic INR had an ETP < 400. Considering this threshold, 93% of severe hemophilia patients, 70% of patients with FVIII 1-19% and 52% of patients with FVIII 20-50% had an ETP < 400. Conclusion In severe hemophilia patients, TG was comparable to that in patients with a therapeutic INR. In one-third of non-severe hemophilia patients, TG was higher. These results suggest that anticoagulation therapy should be considered in a substantial proportion of non-severe hemophilia patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. de Koning MLY, Fischer K, de Laat B, et al. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. J Thromb Haemost. 2017. PMID: 28296129. doi:10.1111/jth.13674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。